GLP-1 Family Research Peptides Explained: Retatrutide, Tirzepatide, Semaglutide, Cagrilintide, and the Incretin-Receptor Landscape

For laboratory and research use only. Not for human consumption.

GLP-1 Family Research Peptides Explained: Retatrutide, Tirzepatide, Semaglutide, Cagrilintide, and the Incretin-Receptor Landscape

Why This Receptor Family Dominates Current Metabolic-Peptide Research

Few areas of peptide research have moved as quickly in the past several years as the GLP-1/GIP/glucagon receptor family. What began as a single-receptor concept — GLP-1 receptor agonism, exemplified by semaglutide — has expanded into a design space where researchers now study molecules that engage two or three structurally related receptors simultaneously. Understanding why that matters requires understanding the receptor biology itself, which is covered in full in our dedicated GLP-1, GIP, and glucagon receptor biology explainer. This hub page exists to orient researchers across that landscape: what distinguishes each molecule, what the published literature has measured about each, and where to find the deeper compound-specific and comparison articles on this site.

The Receptor Biology in Brief

GLP-1, GIP, and glucagon receptors are all class B G-protein-coupled receptors with related but distinct downstream signaling profiles. GLP-1 and GIP are both incretin hormones — released from the gut in response to nutrient intake — while glucagon receptor signaling is more traditionally associated with hepatic glucose output. What makes this family interesting to researchers is that a single engineered peptide backbone can be tuned to activate one, two, or all three of these receptors, and each combination produces a distinct pharmacological profile in study models. Willard et al. (2020) demonstrated this directly with tirzepatide, showing it functions as an "imbalanced and biased" dual agonist — meaning its activity at the GIP and GLP-1 receptors is not symmetric, but shifted toward a specific signaling character rather than simply summing two independent effects. The full mechanistic breakdown of receptor structure, signaling cascades, and why agonist "bias" matters is covered in our receptor biology explainer.

Single, Dual, and Triple Agonists: Why Molecular Design Matters

Semaglutide: The Single-Receptor Reference Point

Semaglutide is a GLP-1 receptor agonist and the molecule against which most of this receptor family is still benchmarked in the literature. Wilding et al. (2021), in the STEP 1 trial, studied once-weekly semaglutide in a population of adults with overweight or obesity and reported outcome measures that subsequent dual- and triple-agonist trials have used as a comparative baseline. Semaglutide is an FDA-approved prescription drug, and it is covered on this site strictly as an informational reference point — it is not sold here, and nothing in this section should be read as guidance toward human use. Readers researching this molecule specifically can find a full compound overview at our semaglutide research overview.

Tirzepatide: Dual GLP-1/GIP Agonism

Tirzepatide adds GIP receptor engagement on top of the GLP-1 mechanism. Frías et al. (2021), in the SURPASS-2 trial, directly compared tirzepatide against semaglutide once weekly in a population of patients with type 2 diabetes, and the trial's head-to-head design has made it a frequent reference point for researchers studying whether dual-receptor engagement changes outcome measures relative to single-receptor agonism. Willard et al. (2020) provides the underlying receptor pharmacology explaining tirzepatide's biased signaling profile at each receptor. Like semaglutide, tirzepatide is FDA-approved and is covered here informationally only. See the full compound overview at our tirzepatide research overview.

Survodutide and Mazdutide: Dual GLP-1/Glucagon Agonism

A separate dual-agonist design pairs GLP-1 receptor activity with glucagon receptor activity instead of GIP. Blüher, Rosenstock, et al. (2024) studied dose-response effects of survodutide, a dual glucagon/GLP-1 receptor agonist, in a population with type 2 diabetes, reported in Diabetologia. Ji, Jiang, et al. (2023) ran a phase 2 randomized controlled trial of mazdutide — a comparable GLP-1/glucagon dual-agonist design — in a Chinese cohort of overweight adults and adults with obesity, published in Nature Communications. Both molecules illustrate an alternative route to multi-receptor engagement than the GIP-based pairing used by tirzepatide. Full compound overviews are available for survodutide and mazdutide.

Retatrutide: Triple GIP/GLP-1/Glucagon Agonism

Retatrutide extends the design space furthest, engaging all three receptors — GIP, GLP-1, and glucagon — in a single molecule. Coskun et al. (2022) described the discovery and preclinical characterization of retatrutide (referred to in that paper by its development code, LY3437943), documenting its engineered affinity across all three receptor targets. Jastreboff, Kaplan, Frías, et al. (2023) then reported a phase 2 trial of retatrutide in NEJM, studying the triple-receptor agonist in a population with obesity. Because retatrutide combines mechanisms studied separately in the dual-agonist and single-agonist literature above, researchers frequently want to understand the molecular engineering behind that triple-receptor design — covered in depth in our article on retatrutide's triple-agonist molecular design — and the general compound landscape in our retatrutide research overview.

The Amylin Axis: Cagrilintide and Combination Approaches

Amylin receptor biology sits adjacent to, but mechanistically distinct from, the GLP-1/GIP/glucagon family. Cagrilintide is a long-acting amylin analog engineered using fatty-acid acylation for extended half-life — a design strategy conceptually similar to the acylation approaches used elsewhere in this receptor family. Kruse, Hansen, et al. (2021) described the development of cagrilintide as a long-acting amylin analogue in the Journal of Medicinal Chemistry, characterizing the chemistry behind its extended pharmacokinetic profile. That fatty-acid acylation chemistry — and how it shapes half-life specifically — is broken down further in our article on cagrilintide's fatty-acid acylation and half-life, and the full compound profile is covered in our cagrilintide research overview.

A separate and distinct research question is what happens when cagrilintide is coadministered with a GLP-1 receptor agonist — a combination sometimes referred to as "Cagrisema." It is important to be precise here: Garvey et al. (2025), in the REDEFINE 1 trial reported in NEJM, studied coadministered cagrilintide and semaglutide together as a combination, in a population of adults with overweight or obesity — this trial is a study of the combination, not of cagrilintide in isolation. Because that combination contains semaglutide, it is treated informationally on this site in the same way semaglutide itself is, with no purchase pathway offered. The full breakdown is available at our Cagrisema research overview.

Pharmacokinetics: Half-Life, Reconstitution, and Concentration Math

Beyond receptor pharmacology, researchers working with retatrutide as a research-use-only material also need to understand its handling characteristics — circulating half-life relevant to study design, and the practical concentration math involved in reconstituting lyophilized peptide for bench use. Our retatrutide half-life and pharmacokinetics article walks through what the published literature, including Coskun et al. (2022) and Jastreboff et al. (2023), reports about the compound's pharmacokinetic profile in study populations. Separately, our reconstitution and mg-to-mL concentration math guide walks through the arithmetic of preparing a working solution from lyophilized powder, and our standalone reconstitution calculator automates that math for any target concentration.

Head-to-Head: How the Published Literature Compares These Molecules

Because these compounds are frequently studied against one another, a cluster of comparison articles on this site sits underneath this hub. Our three-way retatrutide vs. tirzepatide vs. semaglutide comparison lays the single-, dual-, and triple-agonist mechanisms side by side using the trial data cited throughout this page. For readers who want a more focused pairwise breakdown, retatrutide vs. tirzepatide isolates the triple- versus dual-agonist question directly, while tirzepatide vs. semaglutide revisits the SURPASS-2 head-to-head design from Frías et al. (2021) in detail. Because the amylin axis is a genuinely separate mechanism from incretin-receptor agonism, our Cagrisema vs. retatrutide comparison is also worth reading for anyone trying to understand how amylin-plus-GLP-1 coadministration differs mechanistically from triple incretin-receptor agonism in a single molecule.

Sourcing Retatrutide for Laboratory Research

Of the compounds discussed on this page, retatrutide is the only one available on this site, listed as a research-use-only material at retatrutide 20mg. Semaglutide and tirzepatide, as FDA-approved prescription drugs, are not sold here and nothing on this page should be interpreted as a pathway toward obtaining them outside a prescription. Researchers evaluating any research peptide source — including this one — should review third-party batch testing before use; our testing and certificate-of-analysis page documents how retatrutide and other catalog compounds are verified.

References

• Coskun T, Urva S, Roell WC, et al. (2022). "LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept." Cell Metabolism, 34(9). PMID 35985340.
• Jastreboff AM, Kaplan LM, Frías JP, et al. (2023). "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." NEJM, 389. PMID 37366315.
• Willard FS, et al. (2020). "Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist." JCI Insight. PMID 32730231.
• Frías JP, et al. (2021). "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes" (SURPASS-2). NEJM, 385:503-515. PMID 34170647.
• Wilding JPH, et al. (2021). "Once-Weekly Semaglutide in Adults with Overweight or Obesity" (STEP 1). NEJM, 384. PMID 33567185.
• Kruse T, Hansen JL, et al. (2021). "Development of Cagrilintide, a Long-Acting Amylin Analogue." Journal of Medicinal Chemistry, 64(15). PMID 34288673.
• Garvey WT, et al. (2025). "Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity" (REDEFINE 1). NEJM, 393(7):635-647. PMID 40544433.
• Blüher M, Rosenstock J, et al. (2024). "Dose-response effects...of survodutide, a dual glucagon/GLP-1 receptor agonist...in people with type 2 diabetes." Diabetologia, 67. PMID 38095657.
• Ji L, Jiang H, et al. (2023). "A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity." Nature Communications, 14. PMID 38092790.

FAQ

What distinguishes a triple agonist like retatrutide from a dual agonist like tirzepatide?

A dual agonist such as tirzepatide is designed to activate two receptors — GLP-1 and GIP. A triple agonist such as retatrutide is designed to activate three — GLP-1, GIP, and glucagon. Coskun et al. (2022) characterized retatrutide's engineered affinity across all three receptor targets, and researchers study whether adding glucagon-receptor activity changes the metabolic profile observed in preclinical and clinical models compared with dual- or single-receptor molecules.

Why are semaglutide and tirzepatide listed as informational only on this site?

Semaglutide and tirzepatide are FDA-approved prescription drugs indicated for human medical use. Because of that regulatory status, Optimized Aminos does not sell them and does not frame this page as a purchase pathway for either compound. They are covered here strictly as reference points in the receptor-family literature. Retatrutide is the only compound in this family available on this site as a research-use-only material.

Is cagrilintide the same thing as Cagrisema?

No, and the distinction matters for citation accuracy. Cagrilintide alone is a long-acting amylin-receptor analog studied on its own, as described by Kruse et al. (2021). Cagrisema refers to cagrilintide coadministered with semaglutide as a combination. The REDEFINE 1 trial reported by Garvey et al. (2025) studied that coadministered combination, not cagrilintide in isolation — this page cites each study only for the specific formulation it actually tested.

What does "incretin receptor" mean in this context?

Incretins are the gut-derived hormone signals — GLP-1 and GIP — that the body releases after nutrient intake to modulate insulin secretion. "Incretin receptor" research peptides are synthetic analogs engineered to bind and activate the GLP-1 and/or GIP receptors, sometimes alongside the structurally related glucagon receptor, to study downstream metabolic signaling in research models.

Where can I find reconstitution math for retatrutide?

The mg-to-mL concentration math for retatrutide is covered in a dedicated article, and a general-purpose calculator for research reconstitution math is available as a standalone tool on this site.

For laboratory and research use only. Not for human consumption.